Hepatic Venous Pressure Gradient-guided Versus Standard Beta-blocker Therapy in Primary Prevention of Variceal Bleeding
NCT ID: NCT01618890
Last Updated: 2019-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
78 participants
INTERVENTIONAL
2012-09-30
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hepatic venous pressure gradient (HVPG)-directed primary prophylaxis with nonselective beta-blocker therapy (NSBB) leads to a reduction in first variceal bleeding episodes and is cost-effective in the long term.
Study design:
A multi-center randomized controlled study comparing nonselective beta-blocker therapy guided by the hemodynamic response as determined by the difference in HVPG before and after starting oral NSBB therapy, to standard heart rate-guided NSBB therapy in patients with esophageal varices due to liver cirrhosis without a history of esophageal variceal hemorrhage.
Primary study parameters/outcome of the study:
First variceal bleeding episodes occurring within the first two years.
Secondary study parameters/outcome of the study:
* Mortality
* Occurrence of other cirrhosis-related complications
* Occurrence of hepatocellular carcinoma
* Costs of treatments
* Adverse effects
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HVPG-Guided Therapy Versus EVL Plus NSBB in Second Prophylaxis of Esophageal Variceal Bleeding
NCT03687216
Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding
NCT00409084
Standard Therapy and TIPS for Moderate to High-risk Esophageal and Gastric Variceal Bleeding
NCT06013670
EBL Versus EBL and Propranolol for the Prevention of Variceal Rebleeding in Pts With Previous Variceal Treatment
NCT00966082
EUS-PPG Alteration After Ligation and Sclerotherapy in Esophageal Varices
NCT07253090
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
About 50% of cirrhotic patients who use nonselective beta-blockers (NSBB) for primary prevention of variceal bleeding do not reach target hemodynamic response, defined as HVPG \< 12 mmHg or a \> 20% decrease in HVPG from baseline. These so-called hemodynamic nonresponding patients have significantly higher rate of first esophageal variceal hemorrhage as compared to patients who do respond to NSBB.
International institutions that publish guidelines differ in their recommendations concerning HVPG monitoring. As a result, practice currently varies widely.
The investigators hypothesize that HVPG-directed primary prophylaxis leads to a reduction in first variceal bleeding episodes and is cost-effective in the long term.
Objective of the study:
To determine cost-effectiveness of hepatic venous pressure gradient (HVPG)-guided nonselective beta-blocker therapy as compared to standard heart rate-guided beta-blocker therapy in the primary prevention of esophageal variceal bleeding in cirrhotic patients.
Study design:
A multi-center randomized controlled study comparing nonselective beta-blocker therapy guided by the hemodynamic response as determined by the difference in HVPG before and after starting oral nonselective beta-blockers, to standard heart rate-guided nonselective beta-blocker therapy in patients with esophageal varices due to liver cirrhosis.
Study population:
Patients with liver cirrhosis and large (\>5 mm) esophageal varices without a history of esophageal variceal hemorrhage.
Intervention:
-In HVPG-group: Perform baseline HVPG measurement, then start propranolol 20 mg orally twice daily (BID), increase the dose stepwise with 3 days interval to decrease the heart rate to maximum tolerated dose. After 4 weeks a second HVPG is performed.
In hemodynamic responders (who reach target decrease in HVPG) NSBB are continued until end of follow-up.
In hemodynamic nonresponders (who do not reach target decrease in HVPG), NSBB are continued and repeated endoscopic band ligation is performed with 2-4 weeks interval until complete obliteration of large varices.
-In control group: Start propranolol 20 mg BID, increase the dose stepwise with 3 days interval to maximum heart rate-guided tolerated dose.
Primary study parameters/outcome of the study:
First variceal bleeding episodes occurring within the first two years.
Secondary study parameters/outcome of the study:
Mortality Occurrence of other cirrhosis-related complications Occurrence of hepatocellular carcinoma Costs of treatments Adverse effects
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HVPG-propranolol arm
A baseline hepatic venous pressure gradient measurement (HVPG measurement) is performed in day-care setting. After this procedure propranolol is started at 20 mg BID. with dose escalation as described in the propranolol arm.
A second HVPG measurement is performed at 4 weeks after adequate propranolol therapy. In patients who reach target HVPG reduction (responders), propranolol is continued at the same dose without routine control endoscopy. In patients who do not reach target HVPG reduction (nonresponders), endoscopic band ligation is performed in day-care setting with intervals of 2-4 weeks until complete obliteration of varices. Follow-up endoscopy with 6 months interval is performed to detect and treat recurrent large varices.
Hepatic venous pressure gradient measurement
Perform baseline HVPG measurement, then start propranolol 20 mg orally twice daily (BID), increase the dose stepwise to maximum tolerated dose. After 4 weeks a second HVPG is performed.
In hemodynamic nonresponders from the study arm, repeated endoscopic band ligation is performed in daycare setting with intervals of 2-4 weeks.
In hemodynamic responders (HVPG second measurement\< 12 mmHg or \>20% reduction in HVPG compared to baseline) beta-blockers are continued until end of follow-up.
Propranolol arm
Propranolol start 20 mg BID. orally with dose escalation based on heart frequency (HF) with 3-days interval to the maximum tolerated dose. No routine control endoscopy is required.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hepatic venous pressure gradient measurement
Perform baseline HVPG measurement, then start propranolol 20 mg orally twice daily (BID), increase the dose stepwise to maximum tolerated dose. After 4 weeks a second HVPG is performed.
In hemodynamic nonresponders from the study arm, repeated endoscopic band ligation is performed in daycare setting with intervals of 2-4 weeks.
In hemodynamic responders (HVPG second measurement\< 12 mmHg or \>20% reduction in HVPG compared to baseline) beta-blockers are continued until end of follow-up.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnancy
* Contraindications to beta-blocker therapy
* Esophageal varices in the absence of liver cirrhosis
* Intermediate, advanced or terminal stage hepatocellular carcinoma (BCLC stage B, C or D)
* Refractory ascites
* Hepatorenal syndrome
* Prior treatment or prophylaxis for esophageal varices or varices bleeding (propranolol use, TIPS, endoscopic banding ligation, endoscopic sclerotherapy)
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
OTHER
Free University Medical Center
OTHER
Haga Hospital
OTHER
Universitaire Ziekenhuizen KU Leuven
OTHER
Ziekenhuis Netwerk Antwerpen (ZNA)
OTHER
Leiden University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. M.J.Coenraad
Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Minneke Coenraad, Dr.
Role: PRINCIPAL_INVESTIGATOR
Leiden University Medical Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitair Ziekenhuis Antwerpen
Antwerp, , Belgium
Universitaire Ziekenhuizen Leuven
Leuven, , Belgium
Academisch Medisch Centrum
Amsterdam, , Netherlands
Free University Medical Centre
Amsterdam, , Netherlands
Leiden University Medical Centre
Leiden, , Netherlands
Haga Hospital
The Hague, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Thomas Vanwolleghem
Role: primary
Frederik Nevens, Prof. dr.
Role: primary
Ulrich Beuers, Prof.dr.
Role: primary
Karin van Nieuwkerk, Dr.
Role: primary
Jan Nicolaï, Dr.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LUMC-40226
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.